- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 261/02 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
Patent holdings for IPC class C07D 261/02
Total number of patents in this class: 105
10-year publication summary
|
4
|
7
|
4
|
6
|
3
|
9
|
8
|
3
|
8
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Syngenta Participations AG | 3030 |
8 |
| Enanta Pharmaceuticals, Inc. | 424 |
5 |
| Theravance Biopharma R&D IP, LLC | 518 |
5 |
| Syngenta Crop Protection, LLC | 196 |
3 |
| Syngenta Limited | 482 |
3 |
| Medshine Discovery Inc. | 608 |
3 |
| Bristol-myers Squibb Company | 4865 |
2 |
| Syngenta Crop Protection AG | 4911 |
2 |
| Abbvie Inc. | 1784 |
2 |
| Denali Therapeutics Inc. | 228 |
2 |
| Infinity Discovery, Inc. | 19 |
2 |
| National Institute of Biological Sciences, Beijing | 95 |
2 |
| Neuropro Therapeutics, Inc. | 15 |
2 |
| Nissan Chemical Industries, Ltd. | 1757 |
2 |
| Paratek Pharmaceuticals, Inc. | 112 |
2 |
| Nuvalent, Inc. | 37 |
2 |
| Merck Sharp & Dohme LLC | 3752 |
2 |
| Advancion Corporation | 105 |
2 |
| BASF SE | 20421 |
1 |
| Merck Sharp & Dohme Corp. | 2217 |
1 |
| Other owners | 52 |